Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1980 Jul;35(7):531–535. doi: 10.1136/thx.35.7.531

Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis.

M Kattan, A Mansell, H Levison, M Corey, I R Krastins
PMCID: PMC471328  PMID: 6449095

Abstract

The responses of 20 patients with cystic fribrosis to a B2 agonist, salbutamol, to an anticholinergic agent, SCH 1000, and to a placebo containing difluorodichloroethane and soya lecithin delivered by metered aerosol were compared. Flow rates decreased significantly after placebo (p < 0.05). FEV1 increased significantly after salbutamol (p < 0.05), but the degree of these changes was small. There was a small but significant increase in FVC but no change in flow rates after SCH 1000. Specific conductance increased significantly (p < 0.01) after both salbutamol and SCH 1000. Thoracic gas volume remained unchanged with both drugs and placebo. Four of 20 patients had a clinically significant increase in flow rates with SCH 1000 and three with salbutamol. The consistent increases in sGaw coupled with minimal changes in flow rates, suggest that the physiological effects of both agents is to increase the compressibility of the airway. The results after placebo demonstrate the increased airway reactivity to irritants in cystic fibrosis. In view of this, attention should be paid to the possible irritant effects of inhaled medications.

Full text

PDF
531

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouhuys A. Pulmonary response to bronchodilators. Am Rev Respir Dis. 1974 Dec;110(6 Pt 2):119–121. doi: 10.1164/arrd.1974.110.6P2.119. [DOI] [PubMed] [Google Scholar]
  2. Bouhuys A., Van de Woestijne K. P. Mechanical consequences of airway smooth muscle relaxation. J Appl Physiol. 1971 May;30(5):670–676. doi: 10.1152/jappl.1971.30.5.670. [DOI] [PubMed] [Google Scholar]
  3. Brooks S. M., Mintz S., Weiss E. Changes occurring after freon inhalation. Am Rev Respir Dis. 1972 Apr;105(4):640–643. doi: 10.1164/arrd.1972.105.4.640. [DOI] [PubMed] [Google Scholar]
  4. Coburn R. F., Thornton D., Arts R. Effect of trachealis muscle contraction on tracheal resistance to airflow. J Appl Physiol. 1972 Mar;32(3):397–403. doi: 10.1152/jappl.1972.32.3.397. [DOI] [PubMed] [Google Scholar]
  5. DUBOIS A. B., BOTELHO S. Y., BEDELL G. N., MARSHALL R., COMROE J. H., Jr A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest. 1956 Mar;35(3):322–326. doi: 10.1172/JCI103281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Engelhardt A., Klupp H. The pharmacology and toxicology of a new tropane alkaloid derivative. Postgrad Med J. 1975;51(7 Suppl):82–85. [PMC free article] [PubMed] [Google Scholar]
  7. Featherby E. A., Weng T. R., Levison H. The effect of isoproterenol on airway obstruction in cystic fibrosis. Can Med Assoc J. 1970 Apr 25;102(8):835–838. [PMC free article] [PubMed] [Google Scholar]
  8. Gross M. J. Sch 1000: a new anticholinergic bronchodilator. Am Rev Respir Dis. 1975 Dec;112(6):823–828. doi: 10.1164/arrd.1975.112.6.823. [DOI] [PubMed] [Google Scholar]
  9. Kattan M., Keens T. G., Mellis C. M., Levison H. The response to exercise in normal and asthmatic children. J Pediatr. 1978 May;92(5):718–721. doi: 10.1016/s0022-3476(78)80135-8. [DOI] [PubMed] [Google Scholar]
  10. Landau L. I., Phelan P. D. The variable effect of a bronchodilating agent on pulmonary function in cystic fibrosis. J Pediatr. 1973 May;82(5):863–868. doi: 10.1016/s0022-3476(73)80085-x. [DOI] [PubMed] [Google Scholar]
  11. Landau L. I., Taussig L. M., Macklem P. T., Beaudry P. H. Contribution of inhomogeneity of lung units to the maximal expiratory flow-volume curve in children with asthma and cystic fibrosis. Am Rev Respir Dis. 1975 Jun;111(6):725–731. doi: 10.1164/arrd.1975.111.6.725. [DOI] [PubMed] [Google Scholar]
  12. Larsen G. L., Barron R. J., Cotton E. K., Brooks J. G. A comparative study of inhaled atropine sulfate and isoproterenol hydrochloride in cystic fibrosis. Am Rev Respir Dis. 1979 Mar;119(3):399–407. doi: 10.1164/arrd.1979.119.3.399. [DOI] [PubMed] [Google Scholar]
  13. Lifschitz M. I., Denning C. R. Assessment of bronchospasm in patients with cystic fibrosis. Am Rev Respir Dis. 1969 Mar;99(3):399–405. doi: 10.1164/arrd.1969.99.3.399. [DOI] [PubMed] [Google Scholar]
  14. Lorber D. B., Kaltenborn W., Burrows B. Responses to isoproterenol in a general population sample. Am Rev Respir Dis. 1978 Nov;118(5):855–861. doi: 10.1164/arrd.1978.118.5.855. [DOI] [PubMed] [Google Scholar]
  15. McFadden E. R., Jr, Newton-Howes J. Acute effects of inhaled isoproterenol on the mechanical characteristics of the lungs in normal man. J Clin Invest. 1970 Apr;49(4):779–790. doi: 10.1172/JCI106291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mellins R. B., Levin O. R., Ingram R. H., Jr, Fishman A. P. Obstructive disease of the airways in cystic fibrosis. Pediatrics. 1968 Mar;41(3):560–573. [PubMed] [Google Scholar]
  17. Mellis C. M., Levison H. Bronchial reactivity in cystic fibrosis. Pediatrics. 1978 Mar;61(3):446–450. [PubMed] [Google Scholar]
  18. Mitchell I., Corey M., Woenne R., Krastins I. R., Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. J Pediatr. 1978 Nov;93(5):744–748. doi: 10.1016/s0022-3476(78)81070-1. [DOI] [PubMed] [Google Scholar]
  19. Petrie G. R., Palmer K. N. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br Med J. 1975 Feb 22;1(5955):430–432. doi: 10.1136/bmj.1.5955.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Poppius H., Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J. 1973 Oct 20;4(5885):134–136. doi: 10.1136/bmj.4.5885.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pride N. B., Permutt S., Riley R. L., Bromberger-Barnea B. Determinants of maximal expiratory flow from the lungs. J Appl Physiol. 1967 Nov;23(5):646–662. doi: 10.1152/jappl.1967.23.5.646. [DOI] [PubMed] [Google Scholar]
  22. Sterling G. M., Batten J. C. Effect of aerosol propellants and surfactants on airway resistance. Thorax. 1969 Mar;24(2):228–231. doi: 10.1136/thx.24.2.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Storms W. W., DoPico G. A., Reed C. E. Aerosol Sch 1000. An anticholinergic bronchodilator. Am Rev Respir Dis. 1975 Apr;111(4):419–422. doi: 10.1164/arrd.1975.111.4.419. [DOI] [PubMed] [Google Scholar]
  24. Vincent N. J., Knudson R., Leith D. E., Macklem P. T., Mead J. Factors influencing pulmonary resistance. J Appl Physiol. 1970 Aug;29(2):236–243. doi: 10.1152/jappl.1970.29.2.236. [DOI] [PubMed] [Google Scholar]
  25. Zapletal A., Motoyama E. K., Gibson L. E., Bouhuys A. Pulmonary mechanics in asthma and cystic fibrosis. Pediatrics. 1971 Jul;48(1):64–72. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES